Home › Diffuse Large B-Cell Lymphoma › Virginia › Richmond
Diffuse Large B-Cell Lymphoma clinical trials in Richmond, VA
11 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Richmond (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- Virginia Cancer Institute ( Site 0148), Richmond
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
- VCU Health Adult Outpatient Pavillion ( Site 0138), Richmond
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RecruitingPhase 2
- VCU Massey Comprehensive Cancer Center, Richmond
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- Virginia Commonwealth University-Massey Cancer Center, Richmond
A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
- Massey Cancer Center, Richmond
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RecruitingPhase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
RecruitingPhase 2
- VCU Massey Comprehensive Cancer Center, Richmond
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Virginia Commonwealth University Massey Cancer Center, Richmond
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
RecruitingPhase 1/2
- VCU Massey Comprehensive Cancer Center, Richmond
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- Virginia Commonwealth University-Massey Cancer Center, Richmond
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
RecruitingPhase 2
- Virginia Commonwealth University, Richmond
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY20 studies
- Baldwin Park, CA19 studies
- Los Angeles, CA18 studies
- Houston, TX18 studies
- Chicago, IL18 studies
- Milwaukee, WI17 studies
- Nashville, TN17 studies
- Boston, MA17 studies
- Philadelphia, PA15 studies
- Durham, NC15 studies
- Portland, OR15 studies
- Cleveland, OH13 studies
Other studies in Richmond
- Breast Cancer27 studies
- Non-Small Cell Lung Cancer26 studies
- Prostate Cancer19 studies
- Heart Failure17 studies
- Lung Cancer15 studies
- Cardiovascular Disease13 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Colorectal Cancer13 studies
- Cancer (all types)12 studies
- Metastatic Cancer12 studies
- Steatotic Liver Disease11 studies
- Melanoma11 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.